Results
1 -
10 of
12Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells, Cancer Chemotherapy and Pharmacology Organ distribution and tumor uptake of annamycin, a new anthracycline derivative with high affinity for lipid membranes, entrapped in multilamellar vesicles, Cancer Chemotherapy and Pharmacology Effect of structural modification at the 4, 3?, and 2? positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells, Archivum Immunologiae et Therapiae Experimentalis Lyophilized preliposomal formulation of the non-cross-resistant anthracycline annamycin: effect of surfactant on liposome formation, stability and size, Cancer Chemotherapy and Pharmacology Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer, Cancer Chemotherapy and Pharmacology Phase I study of liposomal annamycin, Cancer Chemotherapy and Pharmacology Differences in Lipoprotein Concentration and Composition Modify the Plasma Distribution of Free and Liposomal Annamycin, Pharmaceutical Research Ongoing phase I and II studies of novel anthracyclines, Cardiovascular Toxicology